Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Yahoo! Finance
higher-risk myelodysplastic syndrome (HR-MDS) failed to meet the primary endpoint of complete response (CR) rate. Tamibarotene is Syros' proprietary, oral, selective RARa agonist. The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed HR-MDS patients with RARa gene overexpression. Per the data readout, the CR rate in the first 190 enrolled patients in the tamibarotene/azacitidine treatment arm was 23.8%, which failed to demonstrate statistical significance over the CR rate of 18.8% observed in the placebo/azacitidine control arm. However, Syros reported that the combo drug was well-tolerated by the total enrolled HR-MDS patient population in the SELECT-MDS-1 study. Moreover, the treatment-related adverse events were similar to those observed in earlier company-sponsored studies. Year to date, shares of SYRS have plunged 95.4% compared with the industry's 3.8% decline. Image Source: Zacks Investment Research
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President [Yahoo! Finance]Yahoo! Finance
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
SYRS
Earnings
- 10/31/24 - Beat
SYRS
Analyst Actions
- 11/1/24 - HC Wainwright
SYRS
Sec Filings
- 12/30/24 - Form 144
- 12/27/24 - Form 144
- 12/13/24 - Form 144
- SYRS's page on the SEC website